Results 181 to 190 of about 9,251,777 (236)

CA 15-3 Serum Levels in Ovarian Cancer

Oncology, 1988
Serum levels of CA 15-3, an antigen expressed by human breast carcinoma cells, were measured in 58 ovarian cancer patients, 24 patients with benign ovarian tumor and 62 patients with benign gynecological conditions. Abnormally high serum CA 15-3 levels were found in 41 of 58 patients (71%) with ovarian cancer.
Scambia S, BENEDETTI PANICI, PIERLUIGI, Baiocchi G, Perrone L, Greggi S, Di Roberto P, Mancuso S.   +6 more
openaire   +3 more sources

CA 15-3 et cancers du sein

La Revue de Médecine Interne, 1994
Resume La place exacte du CA 15-3, en oncosenologie clinique, reste actuellement a definir. D'aucune utilite dans une strategie de depistage et, bein que probablement correle a la masse tumorale initiale, le CA 15-3 apparait egalement depourvu, du moins au stade diagnostique, de toute valeur pronostique independante.
E Antoine, L Kayitalire, M Spielmann
openaire   +1 more source

Human Chorionic Gonadotropin and CA 15-3 Producing Adenocarcinoma

Nuklearmedizin, 1998
Summary50 years old man suffering from primary lung adenocarcinoma presented with high levels of both beta subunit human chorionic gonadotropin (βHCG) and cancer antigen 15-3 (CA 15-3) in the absence of elevated carcinoembrionic antigen (CEA), alfa fetoprotein (AFP) and carbohydrate antigen 19-9 (CA 19-9).
G, Uçkaya, A, Ozet, A, Arpaci, S, Kömürcü   +3 more
openaire   +2 more sources

Tumor Marker CA 15-3 in Hematological Malignancies.

Blood, 2006
Abstract Introduction: CA 15-3 is a glycoprotein expressed in several adenocarcinomas, especially of the breast. It is used to detect recurrent or metastatic disease. Elevated levels can also be found in adenocarcinomas of the ovary, lung, pancreas, and colon, and are also related to benign breast or ovarian disease, endometriosis ...
Charalambos Andreadis, Anestis Zantidis, Zisis Kontoninas, Georg Charisopoulos, Fotios Girtovitis, Georgia Kaiafa, Athanasios Papadopoulos, Zoi Saouli   +7 more
openaire   +1 more source

Informations Réactifs : CA 15-3

Immuno-analyse & Biologie Spécialisée, 2001
Resume Cette rubrique est alimentee par les informations recueillies aupres de l'Agence francaise de securite sanitaire des produits de sante (direction de l'evaluation des dispositifs in vitro, departement diagnostic in vitro, unite enregistrement des reactifs) et des industriels.
openaire   +1 more source

Clinical Applications of CA 15–3

1992
Circulating breast cancer associated tumor markers have several potential clinical uses. Although many circulating molecules have been investigated as putative breast cancer markers, only a few have been found to have sufficient sensitivity and specificity to be useful clinically. Of these, carcinoembryonic antigen (CEA) has been the most commonly used
Daniel F. Hayes, Carlo Tondini, Donald W. Kufe   +2 more
openaire   +1 more source

Analytical requirements and standardization of CA 15—3

Scandinavian Journal of Clinical and Laboratory Investigation, 1995
The CA 15-3 assay could play, probably in combination with cytokeratin markers, a role in the detection of early recurrence and in monitoring therapy in metastatic breast cancer patients. The CA 15-3 assay is, however, not useful for early detection of breast cancer and has no prognostic significance.
openaire   +2 more sources

CSF CA 15-3 in breast cancer-related leptomeningeal metastases

Journal of Neuro-Oncology, 2014
The sensitivity of CSF cytology, the standard method for diagnosis of leptomeningeal metastases (LM), is low. Serum cancer antigen 15-3 (CA 15-3) is frequently used for the monitoring of patients with breast cancer (BC) and is a laboratory test available in most centers.
Emilie, Le Rhun, Andrew, Kramar, Sophie, Salingue, Marie, Girot, Isabelle, Rodrigues, Audrey, Mailliez, Fahed, Zairi, Edgar, Bakhache, Yves Marie, Robin, Sophie, Taillibert, François, Dubois, Jacques, Bonneterre, Marc C, Chamberlain   +12 more
openaire   +2 more sources

CA 15-3 as a tumor marker in gynecological malignancies

Gynecologic Oncology, 1988
Serum levels of CA 15-3 were measured in 778 samples from 270 patients with benign and malignant gynecological conditions. Malignant tumors were present in 180 patients including 58 cases with cancer of the ovary, 47 of the endometrium, 61 of the cervix, and 14 of the vulva.
G. Scambia, BENEDETTI PANICI, PIERLUIGI, G. Baiocchi, L. Perrone, S. Greggi, S. Mancuso   +5 more
openaire   +3 more sources

[Evaluation of CA 15-3 radioimmunoassay].

Gan to kagaku ryoho. Cancer & chemotherapy, 1987
The CA 15-3 RIA kit (Centocor Co.) based on a solid-phase radioimmunoassay was evaluated both experimentally and clinically. The results of a basic study of the reproducibility, recovery and dilution were very satisfactory. Serum levels of CA 15-3 were determined in 211 patients with malignancies including 13 breast cancers, 81 patients with benign ...
Y, Takemori, H, Odani, H, Watanabe, H, Ohta, Y, Satomura, T, Okai, N, Sawabu, M, Mai, N, Hattori, T, Hashimoto   +9 more
openaire   +1 more source